Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293579 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00293579 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 5 participants.
The verdict
NCT00293579, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will estimate overall response rate of pemetrexed in poor risk patients with advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293579
The ClinicalTrials.gov registry entry for NCT00293579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00293579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00293579 about?
NCT00293579 is a clinical study titled "Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer". This study will estimate overall response rate of pemetrexed in poor risk patients with advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.
What is the current status of trial NCT00293579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00293579?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00293579?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.